We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Opthea Ltd (OPT) ADR EACH REPR 5 ORD SHS SPON

Sell:$3.38 Buy:$3.59 Change: $0.01 (0.28%)
NASDAQ:1.15%
Market closed |  Prices as at close on 17 April 2024 | Switch to live prices |
Sell:$3.38
Buy:$3.59
Change: $0.01 (0.28%)
Market closed |  Prices as at close on 17 April 2024 | Switch to live prices |
Sell:$3.38
Buy:$3.59
Change: $0.01 (0.28%)
Market closed |  Prices as at close on 17 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase III registration trials of OPT-302 for wet AMD. It also manufactures OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. The Company’s development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

Contact details

Address:
Suite 0403
Level 4, 650 Chapel Street, South Yarra
MELBOURNE
3141
Australia
Telephone:
+61 (3) 98260399
Website:
https://opthea.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OPT
ISIN:
US68386J2087
Market cap:
$281.76 million
Shares in issue:
662.81 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Australia
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Frederic Guerard
    Chief Executive Officer
  • Peter Lang
    Chief Financial Officer
  • Julie Clark
    Senior Vice President - Clinical Development
  • Bruno Gagnon
    Senior Vice President - Global Clinical Operations
  • Fang Li
    Senior Vice President - Regulatory Affairs
  • Karen Adams
    Vice President - Finance, Company Secretary
  • John Han
    Vice President - Medical Affairs
  • Mark O'neill
    Vice President - Chemistry, Manufacturing and Controls
  • Megan Baldwin
    Chief Innovation Officer, Executive Director
  • Michael Gerometta
    Head - Chemistry, Manufacturing and Controls Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.